Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma

Vemurafenib improves survival in advanced metastatic melanoma, but has rarely been associated with severe skin reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).1,2 Dabrafenib is a BRAF inhibitor that shares a sulfonamide moiety with vemurafenib, and only one prior report documents a switch to dabrafenib after the development of SJS/TEN with vemurafenib.2,3 We report a case of vemurafenib-induced TEN followed by successful transition to full-dose therapy with dabrafenib in a patient with metastatic melanoma.